REG - BiVictriX Therapcts. - Result of General Meeting

Bivictrix TherapeuticsAnnouncement

29/08/2024 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240829:nRSc2138Ca&default-theme=true

RNS Number : 2138C  BiVictriX Therapeutics PLC  29 August 2024

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of
the European Union (Withdrawal) Act 2018. With the publication of this
announcement via a Regulatory Information Service, this inside information is
now considered to be in the public domain.

 

NOT FOR PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES OR AUSTRALIA,
CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH
AFRICA, OR ANY PROVINCE OR TERRITORY THEREOF OR TO OR FOR THE ACCOUNT OF ANY
NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES OR ANY PERSON RESIDENT IN
AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC
OF SOUTH AFRICA.

 

BiVictriX Therapeutics plc

 

("BiVictriX", "BiVictriX Therapeutics" or the "Company")

 

Result of General Meeting

 

Alderley Park, 29 August 2024 - BiVictriX (AIM: BVX), a drug discovery and
development company applying an innovative, proprietary approach to develop a
new class of highly selective, next generation cancer therapeutics, bispecific
antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency,
whilst reducing treatment-related toxicities, announces that at the Company's
General Meeting ("General Meeting") held earlier today, all resolutions put to
the Company's shareholders ("Shareholders") were duly passed.

 

Details of proxy votes received are summarised below:

 

 Resolution Number  Resolution Name                                                         Votes For                      Votes Against

                    No. of shares                                                                       % of shares voted  No. of shares  % of shares voted
 1                  Cancellation Resolution                                                 56,143,735  99.86              80,108         0.14
 2                  Re-registration Resolution and Adoption of New Articles of Association  56,143,735  99.86              80,108         0.14

 

The full text of the resolutions proposed and passed at the General Meeting
can be found in the circular containing, inter alia, the Notice of General
Meeting, which was published and posted to Shareholders on 12 August 2024 and
is available on the Company's website https://bivictrix.com
(https://bivictrix.com) (the "Circular").

 

AIM Delisting

 

Following approval by Shareholders at the General Meeting, the admission of
the ordinary shares of £0.01 each in the capital of the Company ("Ordinary
Shares") to trading on AIM will be cancelled (the "AIM Delisting"). The AIM
Delisting is expected to take place at 7:00 a.m on 11 September 2024
("Cancellation") and, accordingly, the last day of dealings in Ordinary Shares
on AIM is expected to be 10 September 2024.

 

Re-registration as a private company

 

In accordance with the passing of Resolution 2, the Company will re-register
as a private limited company and adopt new articles of association, which is
expected to take place in the week commencing 23 September 2024.

 

Matched Bargain Facility

 

To facilitate future shareholder transactions in the Company's Ordinary
Shares, the Company has appointed JP Jenkins to provide a matched bargain
facility, which will be available upon the date of Cancellation. Upon
Cancellation, full details of the matched bargain facility will be made
available to Shareholders  on the Company's website https://bivictrix.com
(https://bivictrix.com) .

 

Capitalised terms used but not defined in this announcement shall have the
same meaning given to such terms in the Circular.

 

For more information, please contact:

 BiVictriX Therapeutics plc

 Tiffany Thorn, Chief Executive Officer                         Email: info@bivictrix.com

 Michael Kauffman, Non-Executive Chairman

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)                Tel: +44 (0) 20 3470 0470

 Panmure Liberum Limited (Joint Broker)
 Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden

                                                               Tel: +44 (0) 20 3100 2000

 ICR Consilium

 Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe   Tel: +44 (0) 20 3709 5700

                                                               Email: Bivictrix@consilium-comms.com

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical
experience and its proprietary discovery engine to advance a new class of
highly cancer-selective, next-generation precision cancer therapies in one of
the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni®
Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for prolonged
dosing and greater efficacy in the clinic. The Company is advancing its
pipeline to deliver the future of cancer care across a broad range of
haematological and solid cancer indications in areas of high unmet medical
need.

Find out more at www.bivictrix.com (http://www.bivictrix.com/)  and connect
with us on LinkedIn
(https://www.linkedin.com/company/bivictrix-therapeutics-plc/)  and
Twitter @BiVictriX (https://twitter.com/BiVictriX) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMQKLFLZVLBBBZ